Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era

Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era: A Retrospective Cohort Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06038110

Enrollment

150

Registered

2023-09-14

Start date

2007-01-01

Completion date

2024-01-31

Last updated

2023-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Axillary Ultrasound

Brief summary

The investigators aimed to determine if axillary ultrasound can reliably distinguish between patients with limited or high nodal burden, so that the patients with limited nodal burden can potentially avoid chemotherapy and instead receive upfront surgery followed by gene assay testing.

Interventions

DIAGNOSTIC_TESTaxillary ultrasound

usefulness of axillary ultrasound in predicting need for chemotherapy or upfront surgery

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

21 Years to 100 Years

Healthy volunteers

Inclusion criteria

* breast cancer patients with T1-3, HR-positive and HER2-negative disease. * aged≥ 50 years old * had axillary ultrasound prior to operation * axillary lymph node dissection

Exclusion criteria

* Patients with neoadjuvant chemotherapy * bilateral cancers

Design outcomes

Primary

Measure	Time frame	Description
the number of abnormal nodes on ultrasound	from the date of diagnosis to the date of surgery, up to 12 weeks	the number of abnormal nodes on ultrasound which was done at the time of diagnosis will be measured

Countries

Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026